1. Menetrier-Caux G, Montmain MC, Dieu C, et al. Inhibition of the differentiation of dendritic cells from CD34 progenitors by tumor cells: role of interleukin-6 and macrophage colonystimulating factor. Blood. 1998; 92: 4778-4791.
2.
2. Bond A, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000; 6: 1755-1766.
5. Bostwick DG. Renal cell carcinoma. In: Lenhard RE Jr, Osteen RT, Gansler T, eds. Clinical Oncology. Atlanta, Ga: American Cancer Society; 2001: 418.
6.
6. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for aggressive renal cell carcinoma (RCC). Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 1635.
7.
7. Dawson NA, Guo C, Zak R, et al. A phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma. Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 1623.
8.
8. Tamboli P, Prieto VG, Bekele BN, Mathew P. The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas. Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 1641.
9.
9. Parker AS, Cheville JC, Janney CA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol. 2002; 33: 801-805.
10.
10. Blum G, Gazit A, Levitzki A. Development of new IGF-1 receptor kinase inhibitors using catechol mimics. J Biol Chem. 2003; 278: 40442-40454.
11.
11. Epstein SS. Unlabeled milk from cows treated with biosynthetic growth hormones: a case of regulatory abdication. Int J Health Serv. 1996; 26: 173-185.
12.
12. Choi J, Lee SS, Lee HJ. Molecular epidemiology of breast cancer: growth factors, hormone receptors and prognostic factors. Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 386.
13.
13. Thompson JA, Sweand efficacy of EPO906 in patients with advanced renal crdloff J, Escudier B, et al. Phase II trial evaluating the safety ancer. Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 1628.
14.
14. Nanus DM, Garino A, Milowsky MI, Rosmarin A, Larkin M, Dutcher JP. Active chemotherapy for aggressive renal cell carcinoma (RCC). Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 1635.
15.
15. Fishman M, Seigne MB. Immunotherapy of metastatic renal cell cancer. Cancer Control. 2002; 9: 293-304.
16.
16. Rubin D. Mechanisms of multimodality immune therapy for people with cancer. Explore for the Professional. 2002; 11: 6-10.
17.
17. Habtai M, Ye H, Frischer Z, Martin J, Waltzer WC, Malinowski K. Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes. J Urol. 2002; 168: 2216-2219.
18.
18. Parmar S, Rademaker F, Fung BB, Kuzel TM. High dose (HD) IL-2 is associated with durable disease free and clinically important improvement in overall survival in metastatic renal cell cancer (MRCC). Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 1630.
19.
19. Minton K. Immunotherapy down the drain? Editorial comment. Nature Rev Cancer. 2003; 3: 472.
20.
20. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21: 3127-3132.
21.
21. Verra N, Jansen R, Groenewegen G, et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer. 2003; 88: 1346-1351.
22.
22. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003; 95: 741-749.
23.
23. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. The generation of low toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003; 101: 4853-4861.
25. Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol. 2003; 21: 2564-2573.
26.
26. Correale P, Sabatino M, Messinese S, et al. Renal cell carcinoma immunotherapy with granulocyte-macrophage-colonystimulating-factor (GM-CSF) and very low dose subcutaneous (s.c.) interleukin-2 (IL-2). Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 716.
27.
27. Verra N, Jansen R, Groenewegen G, et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer. 2003; 88: 1346-1351.
28.
28. Mier JW. Immunotherapy with low-dose IL-2 in combination with GM-CSF. J Immunother. 2003; 26: 95-96.
29.
29. Gnarra JR, Tory K, Weng Y, et al. Mutation of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994; 7: 85-90.
30.
30. 1996 Annual Report, National Cancer Center Research Center, Japan. 12. Genetics Division. Detection of vascular endothelial growth factor in the sera of renal cell carcinoma patients. Available at: http://www.ncc.go.jp/en/nccri/annrep/1996/12.Genetics.html. Accessed September 10, 2003.
31.
31. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-434.
32.
32. George D, Michaelson D, Oh WK, et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 1548.
33.
33. Escudier B, Venner P, Buckowski R, et al. Phase III trial of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Paper presented at: American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract no. 844.
